Processing...
Clinical Trials for Stomach Cancer
Search
Search
There are 141 active trials for advanced/metastatic stomach cancer.
Click on a trial to see more information.
141 trials meet filter criteria.
Sort by:
TrialFetch AI summary: This trial evaluates IAM1363, an oral, irreversible tyrosine kinase inhibitor targeting HER2 mutations, in adult patients with advanced cancers harboring HER2 alterations who have relapsed or are intolerant to previous therapies, including a subgroup with brain metastases.
ClinicalTrials.gov ID: NCT06253871
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring KRAS mutations (excluding G12R) or KRAS amplification, testing the investigational oral pan-KRAS inhibitor BGB-53038 as monotherapy or in combination with tislelizumab (for nonsquamous NSCLC) or cetuximab (for colorectal cancer). BGB-53038 selectively targets KRAS-mutated or amplified tumors, while sparing NRAS and HRAS.
ClinicalTrials.gov ID: NCT06585488
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic GPC3-expressing solid tumors (including hepatocellular carcinoma, AFP-producing gastric cancer, extragonadal yolk sac tumors, non-dysgerminomas, or GPC3-positive squamous NSCLC) who have ECOG 0-1. Patients will receive the investigational bispecific antibody BGB-B2033 (targeting GPC3 and 4-1BB) alone or combined with the anti-PD-1 antibody tislelizumab.
ClinicalTrials.gov ID: NCT06427941
TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.
ClinicalTrials.gov ID: NCT06242470
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic colorectal, pancreatic, gastric/gastroesophageal junction, or lung cancers that have progressed after standard therapy, testing PF-08046050 (SGN-CEACAM5C), an anti-CEACAM5 antibody-drug conjugate linked to a topoisomerase I inhibitor, as monotherapy and in combination with bevacizumab. Eligible patients must have measurable disease and ECOG 0-1.
ClinicalTrials.gov ID: NCT06131840
TrialFetch AI summary: Eligible patients are adults with advanced or metastatic solid tumors—especially those with CCNE1-amplified ovarian, endometrial, gastric/GEJ, or esophageal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, or HR+ HER2- breast cancer post-CDK4/6 inhibitor—who have exhausted standard therapies, receiving oral NKT3964, a selective CDK2 PROTAC degrader targeting the CDK2/cyclin E pathway.
ClinicalTrials.gov ID: NCT06586957
TrialFetch AI summary: Eligible patients are adults with metastatic solid tumors (ECOG 0-1, measurable disease, adequate organ function) who will receive MDX2001, a tetraspecific antibody that engages T cells via CD3/CD28 and targets TROP2 and c-MET on tumor cells. The trial excludes individuals with major cardiac disease, active brain metastases, uncontrolled infections, or unresolved toxicities.
ClinicalTrials.gov ID: NCT06239194
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including NSCLC, MSS colorectal cancer, pancreatic, gastric/GEJ adenocarcinoma, or head and neck squamous cell carcinoma—with good performance status, to receive BMS-986484 (an investigational anti-FAP biologic) as monotherapy or combined with nivolumab. Eligible patients must have measurable disease by RECIST v1.1 and ECOG 0-1.
ClinicalTrials.gov ID: NCT06544655
TrialFetch AI summary: Adults with advanced solid tumors—such as high grade serous ovarian, squamous NSCLC, triple negative breast, gastric, colorectal, esophageal, bladder, head and neck, and select gynecologic cancers—who have progressed on standard therapies receive oral VLS-1488, a selective inhibitor of the mitotic kinesin KIF18A, given in 28-day cycles. Patients with active CNS metastases, prior KIF18A inhibitor exposure, or MSI-H/dMMR tumors are excluded.
ClinicalTrials.gov ID: NCT05902988
TrialFetch AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors expressing CEACAM5—including colorectal, non-small cell lung, or gastric cancer—who have progressed after standard therapies, to receive investigational BMS-986490 (a first-in-class targeted agent for CEACAM5-expressing malignancies) alone or combined with bevacizumab. Key exclusions include prior anti-CEACAM5 therapy or significant pulmonary toxicity.
ClinicalTrials.gov ID: NCT06730750